A majority of patients with Alzheimer’s disease (AD) experience some form of sleep disruption,
including nocturnal sleep fragmentation, increased daytime napping, decreased slow-…

One of the major puzzles in medical research and public health systems worldwide is
Alzheimer’s disease (AD), reaching nowadays a prevalence near 50 million people. This is a …

… Alzheimer’s disease (LOAD). An exploration of APOE as a new therapeutic culprit has
produced some very encouraging results, proving that the protein holds promise in the context of …

… Alzheimer’s disease (AD) is a progressive brain disease that is attributed by the Alzheimer
… Depending on the stage of the disease, it is characterized by factors that progress to hinder …

Alzheimer's disease (AD), a common neurodegenerative disease in the elderly and the most
prevalent cause of dementia, is characterized by progressive cognitive impairment. The …

… Stem cell therapy for Alzheimer’s disease has broad prospects. … of stem cell therapy for
Alzheimer’s disease, solve possible clinical … of stem cells in the treatment of Alzheimer’s disease. …

In 1907 Alois Alzheimer observed, as he quoted, development of “numerous fibers” and “adipose
saccules” in the brain of his diseased patient Auguste Deter. The neurodegenerative …

Neuroinflammation commences decades before Alzheimer's disease (AD) clinical onset and
represents one of the earliest pathomechanistic alterations throughout the AD continuum. …

Alzheimer’s disease (AD) is the most prevalent form of neurodegenerative disease, … mechanisms
and the influence neuroinflammation has on disease progression. The vast majority of …

Alzheimer’s disease (AD) is a devastating age-related neurodegenerative disorder with an
alarming increasing prevalence. Except for the recently FDA-approved Aducanumab of which …